Stockscreener 앱 받기
6.34
12.04%
0.69
Kala Bio Inc 주식(KALA)의 최신 뉴스
What drives KALA BIO Inc. stock priceOutstanding risk-reward balance - Autocar Professional
Is KALA BIO Inc. a good long term investmentSkyrocketing returns - jammulinksnews.com
What analysts say about Stellantis N.V. stockRemarkable growth - jammulinksnews.com
What analysts say about KALA BIO Inc. stockSuperior portfolio returns - jammulinksnews.com
Is CURR a good long term investmentDynamic investment growth - jammulinksnews.com
KALA BIO Inc. Stock Analysis and ForecastJaw-dropping returns - jammulinksnews.com
KALA BIO (NASDAQ:KALA) Downgraded to “Sell” Rating by Wall Street Zen - Defense World
What makes KALA BIO Inc. stock price move sharplyHigh Return Conservative Stocks - Newser
Why KALA BIO Inc. stock attracts strong analyst attentionMomentum Buy Alert - Newser
How KALA BIO Inc. stock performs during market volatilityFree Wealth-Building Investment Strategies - Newser
All Eyes On KALA's CHASEWill The PCED Trial Make Its Case? - RTTNews
Krystal Biotech doses first patient in EMERALD-1 phase 1/2 trial for neurotrophic keratitis - Ophthalmology Times
LADENBURG THALM/SH SH Initiates Coverage on KALA BIO (NASDAQ:KALA) - Defense World
KALA Bio completes enrollment of CHASE clinical trial - Ophthalmology Times
KALA BIO (NASDAQ:KALA) Upgraded by Wall Street Zen to Hold Rating - Defense World
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Ladenburg Thalmann Initiates KALA BIO at Buy With $12 Price Target - MarketScreener
Kala Pharmaceuticals (KALA) Receives Buy Rating from Ladenburg | KALA Stock News - GuruFocus
Kala Pharmaceuticals (KALA) Receives Buy Rating from Ladenburg - GuruFocus
Kala Bio Announces Completion of Enrollment in Chase Clinical Trial Evaluating Kpi-012 for the Treatment of Persistent Corneal Epithelial Defect - MarketScreener
KALA Completes Patient Enrollment in Phase 2b CHASE Trial for KP - GuruFocus
Kala Pharmaceuticals Completes Enrollment for Phase 2b Trial - TipRanks
Kala Bio completes enrollment in Phase 2b trial for KPI-012 in eye disorder - Investing.com
KALA BIO Completes Patient Enrollment in CHASE Phase 2b Trial for KPI-012, Anticipates Topline Results by Q3 2025 - Quiver Quantitative
KALA BIO Announces Completion of Enrollment in CHASE - GlobeNewswire
KALA BIO Eyes 100,000 Patient Market as Pivotal PCED Trial Completes Enrollment, Q3 Results Ahead - Stock Titan
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discu - GuruFocus
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to - GlobeNewswire
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) - Yahoo Finance
KALA BIO Executives Sell Shares Under 10b5-1 Plans - TradingView
Millennium Management LLC Purchases 17,130 Shares of HBT Financial, Inc. (NASDAQ:HBT) - Defense World
Millennium Management LLC Decreases Stake in KALA BIO, Inc. (NASDAQ:KALA) - Defense World
Nexa Resources S.A. (NYSE:NEXA) Shares Sold by Millennium Management LLC - Defense World
24,353 Shares in T. Rowe Price Floating Rate ETF (NYSEARCA:TFLR) Acquired by Bank of America Corp DE - Defense World
Cadre Holdings, Inc. (NYSE:CDRE) Shares Acquired by Millennium Management LLC - Defense World
Bank of America Corp DE Acquires 2,612 Shares of First Trust Indxx Global Natural Resources Income ETF (NASDAQ:FTRI) - Defense World
Millennium Management LLC Sells 1,791 Shares of Bluerock Homes Trust, Inc. (NYSEAMERICAN:BHM) - Defense World
Ameriprise Financial Inc. Buys 11,012 Shares of Liberty All-Star Growth Fund, Inc. (NYSE:ASG) - Defense World
Kala Bio director Mark Iwicki sells $40,638 in stock By Investing.com - Investing.com South Africa
Kala Bio director Mark Iwicki sells $40,638 in stock - Investing.com India
KALA BIO Executives Sell Shares - TradingView
Pre-market Movers: STSS, SGMT, NIVF, OGEN... - RTTNews
KALA BIO (NASDAQ:KALA) Given “Outperform” Rating at Oppenheimer - Defense World
KALA: Oppenheimer Announces Outperform Rating for Kala Bio | KALA Stock News - GuruFocus
KALA Stock Gains Momentum with Oppenheimer's Positive Outlook | - GuruFocus
KALA Stock Gains Momentum with Oppenheimer's Positive Outlook | KALA Stock News - GuruFocus
3.15%
0.13%
자본화:
|
볼륨(24시간):